Skip to main content
. Author manuscript; available in PMC: 2017 Jan 18.
Published in final edited form as: J Neurol Neuromedicine. 2016;1(6):1–10. doi: 10.29245/2572.942x/2016/6.1061

Figures 8.

Figures 8

Bivariate analysis of DNA content and cyclins following karenitecin treatment:

Subconfluent cultures of T98G and MO59K cells were treated with the indicated concentration of karenitecin in the presence and absence of radiation for 72 hours. Following treatment, the cells were harvested, fixed in ethanol, and permeabilized. The cells were stained using specific antibodies for cyclin D1 or cyclin B1 or the relevant isotype control and with goat anti-mouse FITC. The cells were stained with PI solution and analyzed on a FACScan flow cytometer (Becton Dickinson, San Jose, CA). PI staining was used to view different phases of the cell cycle and the cyclin staining in the G0/G1 and G2/M phase of the cell cycle was estimated using the cell quest program. The graph represents the MFI recorded for cyclin B1 and cyclin D1 staining after subtracting the MFI of the isotype control of each treated sample. Figure 7 reveals the effect of karenitecin on cyclin B1 levels, while Figure 8 reveals the effect of karenitecin on the levels of cyclin D1 in T98G and MO59K cells in the G0/G1 and G2/M phase of the cell cycle.